DISCOVER WHAT NUTRACEUTICALS OPTIMIST IS
A biotech company focused on developing natural solutions.
WHAT IS NUTRACEUTICALS CORPORATION STUDYING?
STUDY GOALS
This study aims to evaluate the effectiveness of an inhaled drug called NC-107 in reducing the severity of anxiety symptoms in adults with Generalized Anxiety Disorder (GAD). It also aims to assess the safety and pharmacokinetics (absorption and distribution in the body) of NC-107.
STUDY DESIGN
Participants aged 18 or older with moderate GAD will be enrolled and randomly assigned to receive either NC-107 or a placebo (inactive substance) inhaler for 4 weeks. Participants will take two puffs from the inhaler twice daily. Anxiety symptom assessments, vital signs, and blood tests will be conducted at regular intervals throughout the study. Blood samples will be taken to measure the levels of NC-107 in the body.
BENEFITS
Participants will receive close monitoring of their anxiety symptoms and overall health throughout the study. They may experience a reduction in their anxiety symptoms if assigned to the NC-107 group. Their participation will contribute to the development of a potential new treatment option for GAD.
RISKS
Potential risks associated with participation include side effects from the investigational drug NC-107, which are currently unknown. There may also be risks associated with blood draws, such as bruising or infection at the puncture site.